Related Experiment Video
Updated: Jul 4, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Regulation of collagen-derived antiangiogenic factors by p53
Sarah Assadian1, Jose G Teodoro
1McGill University, McGill Cancer Center, 3655 Promenade Sir William Osler, Montreal, QC, Canada.
Background:
Evidence suggests that the p53 tumor suppressor protein functions, in part, by limiting tumor angiogenesis. This effect is partly mediated by the ability of p53 to increase production of endogenous angiogenesis inhibitors, such as the collagen-derived antiangiogenic factors (CDAFs), endostatin and tumstatin.
Objective:
To review the clinical and therapeutic implications of CDAFs and their regulation by p53.
Methods:
We highlight the inhibitory role of CDAFs in angiogenesis and summarize evidence that p53 regulates the transcriptional program leading to their expression, synthesis, assembly and activation.
Results/Conclusion:
The p53 gene is mutated in half of all human tumors and such cancers would be predicted to produce lower levels of CDAFs. We therefore believe that p53 function can be partially compensated by therapeutic use of CDAFs, which offers a promising new avenue for cancer treatment.
Insights
The p53 tumor suppressor protein limits tumor growth by boosting antiangiogenic factors. Restoring these factors therapeutically may help treat cancers with mutated p53.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The p53 tumor suppressor protein plays a role in limiting tumor angiogenesis.
- This function is partly mediated by p53's ability to enhance the production of endogenous angiogenesis inhibitors, including collagen-derived antiangiogenic factors (CDAFs) like endostatin and tumstatin.
Purpose of the Study:
- To review the clinical and therapeutic implications of CDAFs.
- To examine the regulation of CDAFs by the p53 protein.
Main Methods:
- Highlighting the inhibitory role of CDAFs in angiogenesis.
- Summarizing evidence for p53's regulation of CDAF expression, synthesis, assembly, and activation.
Main Results:
- The p53 gene is mutated in approximately 50% of human tumors.
- Tumors with p53 mutations are predicted to have reduced levels of CDAFs.
Conclusions:
- Therapeutic administration of CDAFs could potentially compensate for lost p53 function in cancer.
- CDAF-based therapies represent a promising new strategy for cancer treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
The Intrinsic Apoptotic Pathway
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

